Taiwan company to present Phase II trial data for its COVID vaccine

Medigen Vaccine Biologics Corp., a Taiwan-based biopharmaceutical company, said Wednesday it is ready to present the data from the Phase II clinical trials of its COVID-19 vaccine candidate.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)